Mineralys Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
mineralystx.com

Market Cap $479.19M
PE -3
Debt -
Cash $97.27M
EV -
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$153.25M
EBIT	-$168.35M
ROE	-65%
ROA	-63%
Equity	$236.93M
Growth Stability	1
PE	-3.13
PB	2.02
Price/Cash	0.2
Equity CAGR	-5%
Earnings Growth YoY	148%
Earnings Growth QoQ	37%

Equity CAGR 5Y	-5%
Equity CAGR 3Y	-5%
Market Cap	$479.19M
Assets	$268.25M
Cash	$97.27M
Shares Outstanding	48.06M
Working Capital	236.41M
Current Ratio	8.55
Shares Growth 3y	42%
Equity Growth QoQ	-18%
Equity Growth YoY	-10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

SEC Filings

Direct access to Mineralys Therapeutics, Inc. (MLYS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31

Sector Comparison

How does Mineralys Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Mineralys Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Mineralys Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Mineralys Therapeutics, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2022	12/2023	TTM
Net Margins	-	-	-
ROA	-	-34%	-63%
ROE	-	-30%	-65%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2022	12/2023	TTM
Debt over FCF	-	-	-
Debt over Equity	-	-	-
Growth Stability	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-
Earnings YoY growth	-	141%	-
Equity YoY growth	-	-561%	-5%
FCF YoY growth	-	-	-